<unk> , sold under the brand name LysaKare, is a fixed-dose combination medication used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called lutetium (177Lu) oxodotreotide. It contains L-arginine hydrochloride and L-lysine hydrochloride. The most common side effects include nausea and vomiting.<unk>  is also associated with hyperkalaemia (high blood potassium levels), but the frequency of this side effect is not known. Side effects with<unk>  are usually mild or moderate. Radiation from lutetium (177Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney.<unk>  and<unk>  interfere with the passage of lutetium (177Lu) oxodotreotide through these kidney tubules. As a result, the radioactive medicine leaves the body in the urine and the kidneys are exposed to less radiation.<unk>  was approved for medical use in the European Union in July 2019.
Arginine/lysine
Phosphine
Inositol
Gluten
Saline 
Glycoside
Glycogen
Choline